Tigecycline

All Cause Mortality

• All-cause mortality was higher in patients treated with tigecycline than comparators in a meta-analysis of clinical trials. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable.

FDA and Industry Communications

Index to FDA Drug Safety Information

Patient Counseling Information

• TYGACIL

Package Inserts

Tigecycline